Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Pet Pharm Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	130.7	117.87	75.74
Revenue Growth (YoY)	10.89%	55.62%	-
Cost of Revenue	60.74	53.27	39.88
Gross Profit	69.96	64.59	35.86
Selling, General & Admin	49.74	44.16	31.71
Research & Development	12.14	14.05	7.79
Operating Expenses	61.85	57.01	40.7
Operating Income	8.11	7.59	-4.84
Interest Expense	-0.18	-0.18	-0.2
Interest & Investment Income	4.1	1.67	0.45
Other Non Operating Income (Expenses)	0.38	0.07	0.77
Pretax Income	12.42	9.15	-3.81
Income Tax Expense	-2.09	-	-
Net Income	14.51	9.15	-3.81
Net Income to Common	14.51	9.15	-3.81
Net Income Growth	58.54%	-	-
Shares Outstanding (Basic)	40	30	24
Shares Outstanding (Diluted)	40	30	24
Shares Change (YoY)	36.52%	23.94%	-
EPS (Basic)	0.36	0.31	-0.16
EPS (Diluted)	0.36	0.31	-0.16
EPS Growth	16.13%	-	-
Free Cash Flow	-159.51	-22.02	-27.87
Free Cash Flow Per Share	-3.96	-0.75	-1.17
Gross Margin	53.53%	54.80%	47.34%
Operating Margin	6.21%	6.44%	-6.39%
Profit Margin	11.10%	7.76%	-5.03%
Free Cash Flow Margin	-122.05%	-18.68%	-36.80%
EBITDA	27.72	24.34	9.46
EBITDA Margin	21.21%	20.65%	12.49%
D&A For EBITDA	19.6	16.75	14.3
EBIT	8.11	7.59	-4.84
EBIT Margin	6.21%	6.44%	-6.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.